Term
| NK cells help to control --- infections, esp. those caused by --- viruses |
|
Definition
|
|
Term
| NK cells are similar to CD8 cells, except the default for NK cells is to ---unless they are inhibited |
|
Definition
|
|
Term
|
Definition
| NK adhesion to target cells & endothelium |
|
|
Term
|
Definition
| component part of Fc receptor on the NK cell activated when bound to IgG coated target cells--> ADCC |
|
|
Term
|
Definition
| inhibitory receptors, when bound to HLA B, C, NK cell is inhibited |
|
|
Term
|
Definition
| inhibitory receptors, when bound to HLA B, C, NK cell is inhibited |
|
|
Term
|
Definition
| another inhibitory receptor, when bound to HLA E NK cell is inhibited |
|
|
Term
|
Definition
| non-polymorphic MHC I "backup" for KIR system. Leader sequence of HLA E is like that of HL A B C s expression of HLA E is proportional to expansion of other HLA molecules |
|
|
Term
|
Definition
| binds IL-15, important for NK development and survival--contains common gamma chain. people with defects in IL-15R can have bad herpes infections (must treat with bone marrow) |
|
|
Term
|
Definition
| NK cell activating receptors |
|
|
Term
| natural killer cells share a common lineage with other lymphocyte subsets. t or f? |
|
Definition
|
|
Term
| NK cells express the common gamma chain. The cytokines receptors --, --, and -- require this adaptor protein initiate intracellular signaling |
|
Definition
|
|
Term
| CD4+ T cells: express CD3 complex? |
|
Definition
|
|
Term
| CD8+ T cells: express CD3 complex? |
|
Definition
|
|
Term
| NK cells: express CD3 complex? |
|
Definition
|
|
Term
| CD4+ T cells: require a thymus for development? |
|
Definition
|
|
Term
| CD8+ t cells: require a thymus for development? |
|
Definition
|
|
Term
| NK cells: require a thymus for development? |
|
Definition
|
|
Term
| CD4 t cells: require the RAG proteins for development? |
|
Definition
|
|
Term
| CD8:require the RAG proteins for development? |
|
Definition
|
|
Term
| NK cells:require the RAG proteins for development? |
|
Definition
|
|
Term
| CD4: exhibit constitutive cytotoxicity? |
|
Definition
|
|
Term
| CD8:exhibit constitutive cytotoxicity? |
|
Definition
|
|
Term
| NK:exhibit constitutive cytotoxicity? |
|
Definition
|
|
Term
| CD4: Utilize perforin/granzyme or fas-fas ligand killing machine? |
|
Definition
|
|
Term
| CD8 T cells: Utilize perforin/granzyme or fas-fas ligand killing machine? |
|
Definition
|
|
Term
| NK cells: Utilize perforin/granzyme or fas-fas ligand killing machine? |
|
Definition
|
|
Term
| CD4+ T cells: secrete IFN-gamma |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| what is antibody-dependent cellular cytotoxicity (ADCC)? |
|
Definition
| NK cells kill target cells coated (opsonized) with IgG antibodies, use peforin/granzyme, fas-fasligand to kill the target cell |
|
|
Term
| what is x-linked lymphoproliferative syndrome? |
|
Definition
| Deficiency in SAP, an adaptor for 2B4, activation of B cells. patients die of EBV-induced lymphoma (remember EBV is a herpes virus and patients with NK cell problems have issues with these bugs) |
|
|
Term
|
Definition
| recog. peptidoglycan (PGN) |
|
|
Term
|
Definition
| recog. Lipopolysaccharide LPS |
|
|
Term
|
Definition
|
|
Term
|
Definition
| CPG DNA (often seen in bacteria) |
|
|
Term
| Nucleotide binding domain (NOD) |
|
Definition
| recog. conserved pathogen patterns (cytoplasmic) |
|
|
Term
|
Definition
| recog. conserved pathogen patterns |
|
|
Term
| NFKb sign pathway activation |
|
Definition
| production of cytokines & chemokines CXC chemokines |
|
|
Term
| IL-1 and IL1 receptor have----feedback on NFkB |
|
Definition
| Positive feedback on NFkB |
|
|
Term
|
Definition
| pro-inflammatory pathway positive feedback on NFkB. NLAP proteins bind to conserved pathogen patterns. activated and assemble into complex that recruits caspase I-cleaves pro IL-1 and activates into active IL-1 |
|
|
Term
|
Definition
| 1st stage of recruitment of neutrophils into infected tissue. E-selectin binds to sialyl-levis (on neutrophil) |
|
|
Term
|
Definition
| neutrophil stops rolling & binds to endothelium. ICAM-1 binds to LFA-1 on the neutrophil |
|
|
Term
|
Definition
| The neutrophil squeezes through the endothelial cells. **CD31 is an important molecule for this. |
|
|
Term
|
Definition
| neutrophils migrate in response to chemokines |
|
|
Term
|
Definition
| early in innate reponse. attract neutrophils to infection |
|
|
Term
|
Definition
| Later in inflammatory responses attracting other cells, lymphocytes, monocytes, eosinophils, chronic inflammation |
|
|
Term
|
Definition
| Ag that is found on specific tumor cells but not on other cells |
|
|
Term
|
Definition
| found on tumor cells and also on some normal cells |
|
|
Term
| Immunosurveillance theory |
|
Definition
| in addition to protecting us against pathogens and foreign tissues, the immune system protects against cancer |
|
|
Term
| Patients with decreased immune function should be susceptible to more cancers against cancer, and when immune system function is replaced, their cancers should be cured |
|
Definition
| True sometimes, for very rare cancers, like kaposi's sarcoma in HIV+ patients. these cancers are usually virally-induced |
|
|
Term
|
Definition
| trans. immune system components that might react with tumor to patients 1) t cells 2) antibodies |
|
|
Term
|
Definition
| stimulate the patients immune system to mount their own response to the cancer 1) general immune stimulators, IL2, IFN, TLR ligands 2) Tumor vaccines: give tumor associated vaccine along with adjuvant, will mount response against tumor |
|
|
Term
|
Definition
| under passive immunotherpy. isolate tumor infilitrating t cells that react against tumor cells, expand in vitro and give back to patient (Melanoma trials) |
|
|
Term
|
Definition
| under passive: monoclonal antibodies against tumor (usually surface antigens) *Taking advantage of ADCC |
|
|
Term
| General immune stimulators |
|
Definition
| RCC, bladder, IL2, TLR ligans (for active immunotherapy) |
|
|
Term
|
Definition
| Active (give tumor antigens along) w/adjuvant will patient response against tumor |
|
|
